We have located links that may give you full text access.
GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS INCREASE SOLID GASTRIC RESIDUE RATES ON UPPER ENDOSCOPY ESPECIALLY IN COMPLICATED DIABETIC PATIENTS: A CASE CONTROL STUDY.
American Journal of Gastroenterology 2024 March 28
OBJECTIVE: Glucagon-like peptide-1 receptor agonists (GLP-1RA) prescribed for weight loss and type 2 diabetes mellitus (T2DM) can delay gastric emptying but risk factors and impact on procedure outcomes remain unclear.
METHODS: We compared frequency of gastric residue on upper endoscopy in patients on a GLP-1RA and propensity-score matched controls in this retrospective case-control study of consecutive patients undergoing endoscopic procedures over a 3.5 year period. GLP-1RAs were not held before endoscopy. Gastric residue presence was assessed by reviewing endoscopy reports and images. Predictors and consequences of gastric residue with GLP-1RA were determined.
RESULTS: In 306 GLP-1RA users compared to matched controls, rates of gastric residue were significantly higher with GLP-1RA use (14% vs 4%, p<0.01), especially in T2DM patients (14% vs 4%, p < 0.01), with insulin dependence (17% vs. 5%, p<0.01) and T2DM complications (15% vs. 2%, p < 0.01). Lower gastric residue rates were noted after prolonged fasting and clear liquids for concurrent colonoscopy (2% vs 11%, p<0.01), and in patients with afternoon procedures (4% vs 11%, p<0.01). While 22% with gastric residue required intubation and 25% had early procedure termination, no procedural complications or aspiration were recorded.
CONCLUSIONS: GLP-1RA use is associated with increased gastric residue on upper endoscopy, particularly in T2DM patients, surpassing the impact of opiates alone. Risk is highest in the presence of T2DM complications, while prolonged fasting and a clear-liquid diet are protective. This increased risk of gastric residue does not appear to translate to an increased risk of procedural complications.
METHODS: We compared frequency of gastric residue on upper endoscopy in patients on a GLP-1RA and propensity-score matched controls in this retrospective case-control study of consecutive patients undergoing endoscopic procedures over a 3.5 year period. GLP-1RAs were not held before endoscopy. Gastric residue presence was assessed by reviewing endoscopy reports and images. Predictors and consequences of gastric residue with GLP-1RA were determined.
RESULTS: In 306 GLP-1RA users compared to matched controls, rates of gastric residue were significantly higher with GLP-1RA use (14% vs 4%, p<0.01), especially in T2DM patients (14% vs 4%, p < 0.01), with insulin dependence (17% vs. 5%, p<0.01) and T2DM complications (15% vs. 2%, p < 0.01). Lower gastric residue rates were noted after prolonged fasting and clear liquids for concurrent colonoscopy (2% vs 11%, p<0.01), and in patients with afternoon procedures (4% vs 11%, p<0.01). While 22% with gastric residue required intubation and 25% had early procedure termination, no procedural complications or aspiration were recorded.
CONCLUSIONS: GLP-1RA use is associated with increased gastric residue on upper endoscopy, particularly in T2DM patients, surpassing the impact of opiates alone. Risk is highest in the presence of T2DM complications, while prolonged fasting and a clear-liquid diet are protective. This increased risk of gastric residue does not appear to translate to an increased risk of procedural complications.
Full text links
Related Resources
Trending Papers
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease.Rheumatology 2024 April 17
Albumin: a comprehensive review and practical guideline for clinical use.European Journal of Clinical Pharmacology 2024 April 13
Renin-Angiotensin-Aldosterone System: From History to Practice of a Secular Topic.International Journal of Molecular Sciences 2024 April 5
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app